2019
Improved discrimination of mortality with Veterans Aging Cohort Study (VACS) Index 2.0 in HIV-positive individuals
Tate JP, Sterne JAC, Justice AC. Improved discrimination of mortality with Veterans Aging Cohort Study (VACS) Index 2.0 in HIV-positive individuals. AIDS 2019, Publish Ahead of Print: &na;. PMID: 30649058, PMCID: PMC6749990, DOI: 10.1097/qad.0000000000002140.Peer-Reviewed Original ResearchConceptsWhite blood countC-statisticBlood countVeterans Aging Cohort Study (VACS) IndexAntiretroviral Therapy Cohort CollaborationDiscrimination of mortalityVACS Index 2.0Antiretroviral therapy initiationCD4 cell countHIV-positive populationHarrell's C-statisticHIV-1 RNAHIV-positive individualsKaplan-Meier plotsCohort CollaborationNadir CD4VAC patientsAntiretroviral therapyCause mortalityCD8 ratioTherapy initiationViral suppressionGeneral healthExcess mortalityLaboratory values
2016
Do Biomarkers of Inflammation, Monocyte Activation, and Altered Coagulation Explain Excess Mortality Between HIV Infected and Uninfected People?
So-Armah KA, Tate JP, Chang CH, Butt AA, Gerschenson M, Gibert CL, Leaf D, Rimland D, Rodriguez-Barradas MC, Budoff MJ, Samet JH, Kuller LH, Deeks SG, Crothers K, Tracy RP, Crane HM, Sajadi MM, Tindle HA, Justice AC, Freiberg MS. Do Biomarkers of Inflammation, Monocyte Activation, and Altered Coagulation Explain Excess Mortality Between HIV Infected and Uninfected People? JAIDS Journal Of Acquired Immune Deficiency Syndromes 2016, 72: 206-213. PMID: 27824677, PMCID: PMC4867134, DOI: 10.1097/qai.0000000000000954.Peer-Reviewed Original ResearchConceptsBiomarkers of inflammationD-dimerIL-6Uninfected peopleMortality riskHIV infectionMonocyte activationVeterans Aging Cohort Study Biomarker CohortCox proportional hazards regressionElevated IL-6Excess mortality riskProportional hazards regressionUnsuppressed viremiaComorbid diseasesBiomarker cohortHighest quartileHIV statusHazards regressionExcess riskBlood drawExcess mortalityImmunologic processesSCD14Mortality rateLogistic regression
2015
Injection Drug Use and Hepatitis C as Risk Factors for Mortality in HIV-Infected Individuals
May MT, Justice AC, Birnie K, Ingle SM, Smit C, Smith C, Neau D, Guiguet M, Schwarze-Zander C, Moreno S, Guest JL, Monforte A, Tural C, Gill MJ, Bregenzer A, Kirk O, Saag M, Sterling TR, Crane HM, Sterne JA. Injection Drug Use and Hepatitis C as Risk Factors for Mortality in HIV-Infected Individuals. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2015, 69: 348-354. PMID: 25848927, PMCID: PMC4506784, DOI: 10.1097/qai.0000000000000603.Peer-Reviewed Original ResearchConceptsInjection drug useDrug useLiver-related mortalityHepatitis C infectionEffect of HCVMortality hazard ratioNorth American cohortHCV coinfectionHCV statusAntiretroviral therapyC infectionHepatitis CHazard ratioSurvival differencesRisk factorsExcess mortalityPoor survivalRisk groupsHCVAmerican cohortHIVNew treatmentsMortalitySubstantial proportionComplete dataSmoking and life expectancy among HIV-infected individuals on antiretroviral therapy in Europe and North America
Helleberg M, May MT, Ingle SM, Dabis F, Reiss P, Fätkenheuer G, Costagliola D, d’Arminio A, Cavassini M, Smith C, Justice AC, Gill J, Sterne JA, Obel N. Smoking and life expectancy among HIV-infected individuals on antiretroviral therapy in Europe and North America. AIDS 2015, 29: 221-229. PMID: 25426809, PMCID: PMC4284008, DOI: 10.1097/qad.0000000000000540.Peer-Reviewed Original ResearchConceptsMortality rate ratiosCardiovascular diseaseLife expectancyBackground populationNon-AIDS malignanciesAntiretroviral therapy initiationProportion of smokersNorth American cohortSmoking-related mortalityCause of deathMore life yearsAIDS malignanciesAntiretroviral therapyPrevious smokersTherapy initiationSmoking cessationSmoking increasesExcess mortalityAge 35HIVSmokersAmerican cohortSmokingLife yearsHigh mortality
2013
An internationally generalizable risk index for mortality after one year of antiretroviral therapy
Tate JP, Justice AC, Hughes MD, Bonnet F, Reiss P, Mocroft A, Nattermann J, Lampe FC, Bucher HC, Sterling TR, Crane HM, Kitahata MM, May M, Sterne JA. An internationally generalizable risk index for mortality after one year of antiretroviral therapy. AIDS 2013, 27: 563-572. PMID: 23095314, PMCID: PMC4283204, DOI: 10.1097/qad.0b013e32835b8c7f.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAgedAlanine TransaminaseAnti-HIV AgentsAspartate AminotransferasesBiomarkersCD4 Lymphocyte CountCohort StudiesEuropeFemaleHemoglobinsHepatitis CHIV InfectionsHumansMaleMiddle AgedMultiple Organ FailurePlatelet CountPredictive Value of TestsRisk AssessmentRNA, ViralUnited StatesConceptsHIV-1 RNAVeterans Aging Cohort StudyMultiorgan system injuryCD4 cell countAntiretroviral therapyVACS IndexSystem injuryCell countDetectable HIV-1 RNAART Cohort CollaborationOutcome of deathAging Cohort StudyHepatitis C statusMortality risk indexGood discriminationART initiationCohort CollaborationHCV coinfectionCohort studyHIV deathsHIV markersHIV infectionValidation cohortAlanine transaminaseExcess mortality
2009
Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries
Zwahlen M, Harris R, May M, Hogg R, Costagliola D, de Wolf F, Gill J, Fätkenheuer G, Lewden C, Saag M, Staszewski S, d'Arminio Monforte A, Casabona J, Lampe F, Justice A, von Wyl V, Egger M. Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries. International Journal Of Epidemiology 2009, 38: 1624-1633. PMID: 19820106, PMCID: PMC3119390, DOI: 10.1093/ije/dyp306.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAdultAnti-Retroviral AgentsAntiretroviral Therapy, Highly ActiveCause of DeathCD4 Lymphocyte CountCohort StudiesFemaleHIVHIV InfectionsHomosexuality, MaleHumansMaleMortalityPrevalenceProspective StudiesRisk FactorsSubstance Abuse, IntravenousViral LoadVirus ReplicationConceptsCD4 cell countAntiretroviral therapyCells/microLGeneral populationCell countEligible patientsExcess mortalityCopies/Start of ARTViral replicationART Cohort CollaborationCorresponding general populationMortality of HIVPotent antiretroviral therapyCombination antiretroviral therapyPercentage of patientsProspective cohort studyInjection drug useViral load measurementsNumber of deathsCohort CollaborationCohort studyMedian ageViral loadClinical stage